Sign in
Taking people in United StatesPhase 2

BXCL501 After Stress to Increase Recovery Success

Key facts

Who runs it
University of North Carolina, Chapel Hill
Where
Charlottesville, Jacksonville, and St Louis, United StatesSee the 3 sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
100 people, planned
Started
23 Feb 2026
Planned end
29 Sept 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • BXCL501 (dexmedetomidine HCl)
  • Placebo
Record updated
14 April 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • ≥ 18 years and ≤ 65 years of age
  • Admitted to ED within 72 hours of MVC
  • Anticipated to be discharged home from the ED
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Consent to receive unencrypted communications
  • Has a smartphone with continuous service for ≥ 1 year
  • Has a personal email address they regularly access
  • Able to speak and read English
  • Females of childbearing potential (not surgically sterilized (tubal ligation/hysterectomy) or not post-menopausal (no menstrual period for > 12 months)) must be willing to use a medically acceptable and effective birth control method for 3 months before the study and while participating in the study. Medically acceptable methods of contraception that may be used by the participant include abstinence, birth control pills or patches, birth control implants, diaphragm, intrauterine device (IUD), or condoms

Who cannot take part

  • People of childbearing potential who are pregnant, breastfeeding, planning to become pregnant, or not using a highly effective form of contraception (e.g., implants, intrauterine devices (IUDs), tubal ligation, hormonal birth control pills, patches, vaginal rings, or injections) during their participation
  • Chronic daily opioid use prior to MVC (> 20 mg oral daily morphine equivalents)
  • Participation in any other clinical trial of a pharmacological agent within 30 days prior to screening
  • Bipolar disorder, psychotic disorder, active psychosis, suicidal ideation, or homicidal ideation
  • Hypersensitivity or history of allergic reaction to dexmedetomidine
  • Any other history or condition that would, in the site investigator's judgement, indicate that the patient would very likely be non-compliant with the study or unsuitable for the study (e.g., might interfere with the study, confound interpretation, or endanger patient)
  • Clinically significant history of cardiac disease including (a) history of syncope or other syncopal attacks; (b) current evidence of orthostatic hypotension (defined as a decrease in systolic BP of 20 mm Hg or decrease in diastolic BP of 10mm Hg within 3 minutes); (c) resting heart rate of <55 beats per minute; (d) systolic blood pressure <110mmHg or diastolic BP <70mmHg; (e) participants with a QTC interval >440msec (males) or >460msec (females) not in sinus rhythm; or 1st, 2nd or 3rd degree hearth block; or (f) history of severely impaired ventricular function (ejection fraction < 30%)
  • Hypomagnesia (<1.7 mg/dL) or hypokalemia (< 3.0 mEq/L)
  • Substantial hepatic impairment (e.g. AST or ALT > 3 times the upper limit of normal or history of cirrhosis)
  • Currently taking the following medications: a) medications for alcoholism (e.g. naltrexone, disulfiram, topiramate, acamprosate); b) psychotropic medications that promote sedation including sedative/hypnotics, barbiturates, antihistamines, sedative antidepressants (e.g. doxepin, mirtazapine, trazodone), and triptans (e.g., sumatriptan); c) alpha-2-adrenergic agonists (clonidine, guanfacine, lofexidine); d) adrenergic agents prescribed for other reasons (prazosin); e) or medications known to cause QT prolongation. (Permitted Concomitant Medications: The concomitant medications allowed in the study include non-sedative antidepressants used to treat PTSD)
  • Substantial comorbid injury (e.g., long bone fracture)
  • Prisoner status
  • Hospital admission
  • Lacking capacity to provide informed consent (receipt of sedative, hypnotic agent making the patient non-decisional for consent)

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • UVA University HospitalCharlottesville, United StatesContact: Glass George, MD (principal investigator)Taking people
  • University of Florida College of Medicine JacksonvilleJacksonville, United StatesContact: Sophia Sheikh, MD (principal investigator)Taking people
  • Washington University in St. LouisSt Louis, United StatesContact: Stacey House, MD (principal investigator)Not yet recruiting

About the trial

What the trial wants to find out

This study will examine the safety and efficacy of BXCL501 to reduce ASR symptoms and behavioral changes among patients presenting to the Emergency Department (ED) after Motor Vehicle Collision (MVC). Specifically, the investigators will perform the BXCL501 (BASIS) Trial, a double-blind placebo-controlled Randomized Controlled Trial (RCT) to determine if BXCL501 (dexmedetomidine hydrochloride sublingual film) initiated in the ED in the hours after MVC to high risk individuals, treats/reduces ASR/ASD symptoms (primary outcome), improves neurocognitive function, and prevents/reduces posttraumatic stress (PTS) symptoms (secondary outcomes) long term. 100 participants will be randomized, receive study drug in ED and be discharged with a 2-week drug supply. Prior to initial dose of study drug administration, and during the hours, days, and weeks after participants will receive serial longitudinal assessments of psychological and somatic symptoms, neurocognitive function, and adverse events.

The 2 groups in the trial

  • BXCL501 (dexmedetomidine HCl)Treatment being tested

    Participants will be instructed to take an initial dose of BXCL501 (equivalent to 1 film, 120mcg) in the ED as part of enrollment procedures. If the time between the first dose and the planned bedtime of the participant is greater than 6 hours, participants will be instructed to take the second dose at bedtime on the day of enrollment. If the time between the first dose and the planned bedtime of the participant is less than 6 hours participants will be instructed to take the second dose before bedtime on the day following enrollment. Following the initial dosing on the day of enrollment, all participants will be instructed to take a dose of study medication before bedtime until they have completed 14 days of treatment.

  • PlaceboPlacebo, for comparison

    Participants will be instructed to take an initial dose of placebo (equivalent to 1 film, 120mcg) in the ED as part of enrollment procedures. If the time between the first dose and the planned bedtime of the participant is greater than 6 hours, participants will be instructed to take the second dose at bedtime on the day of enrollment. If the time between the first dose and the planned bedtime of the participant is less than 6 hours participants will be instructed to take the second dose before bedtime on the day following enrollment. Following the initial dosing on the day of enrollment, all participants will be instructed to take a dose of study medication before bedtime until they have completed 14 days of treatment.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With a Sublingual Formulation of Dexmedetomidine (BXCL501)
Criteria questions
Built from NCT06943404, who can take part
Record updated
14 April 2026